Bonesupport touts high infection eradication rate in prospective trial

Bonesupport today released data from the prospective trial of its Cerament G injectable antibiotic-eluting bone substitute, touting a 96% infection eradication rate in patients treated with the substitute. Data from the study was published in The Bone and Joint Journal, the company said. Cerament G is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while preventing colonization of microorganisms by eluting the antibiotic gentamicin. “The results that we have achieved with the single stage surgical procedure using Cerament G for the dead space management of patients with chronic osteomyelitis are a significant improvement on past experience. These results reflect Cerament G’s unique local antibiotic delivery profile and its attractive bone remodelling capabilities. We are increasingly using Cerament G in the treatment of patients with chronic osteomyelitis and infected fractures. It allows a more patient-friendly treatment, preventing repeated operations and recurrent infections. We expect it to become the mainstay of our dead space management, given the major clinical and health economic benefits that it supports,” lead author Martin McNally of the U.K.’s Oxford University Hospitals said in a press release. Data from 12-34 month follow ups from the 1st 100 patients in the study indicated...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Orthopedics Bonesupport Source Type: news